iRadimed (NASDAQ:IRMD) Sets New 12-Month High – Here’s Why

by · The Markets Daily

iRadimed Corporation (NASDAQ:IRMD – Get Free Report)’s stock price reached a new 52-week high on Tuesday . The stock traded as high as $93.45 and last traded at $92.82, with a volume of 2946 shares trading hands. The stock had previously closed at $93.22.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Wall Street Zen downgraded iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of iRadimed in a research note on Friday, October 31st. Roth Capital set a $90.00 target price on shares of iRadimed in a research report on Friday, October 31st. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Finally, Lake Street Capital reiterated a “buy” rating and set a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $87.33.

View Our Latest Stock Report on iRadimed

iRadimed Trading Up 0.8%

The stock’s 50-day simple moving average is $80.58 and its 200-day simple moving average is $69.47. The firm has a market capitalization of $1.19 billion, a P/E ratio of 56.92 and a beta of 1.06.

iRadimed (NASDAQ:IRMD – Get Free Report) last released its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.04. The company had revenue of $21.20 million for the quarter, compared to analysts’ expectations of $20.50 million. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, equities research analysts expect that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, November 25th. Investors of record on Friday, November 14th were given a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, November 14th. iRadimed’s dividend payout ratio (DPR) is 41.21%.

Insider Buying and Selling at iRadimed

In related news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $90.36, for a total value of $451,800.00. Following the completion of the sale, the chief executive officer owned 2,307,500 shares in the company, valued at $208,505,700. The trade was a 0.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 50,000 shares of company stock worth $3,840,650. Company insiders own 36.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC grew its position in shares of iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 211 shares during the last quarter. Quarry LP bought a new stake in shares of iRadimed in the 3rd quarter worth approximately $40,000. State of Alaska Department of Revenue bought a new position in iRadimed during the 3rd quarter worth $47,000. Tower Research Capital LLC TRC lifted its stake in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares during the last quarter. Finally, Spire Wealth Management bought a new position in shares of iRadimed during the second quarter worth about $60,000. Institutional investors own 92.34% of the company’s stock.

About iRadimed

(Get Free Report)

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

Read More